Health-related quality of life by gout severity in women and men with gout in primary care: results from a questionnaire study in Western Sweden.


Journal

Scandinavian journal of rheumatology
ISSN: 1502-7732
Titre abrégé: Scand J Rheumatol
Pays: England
ID NLM: 0321213

Informations de publication

Date de publication:
11 2023
Historique:
medline: 17 11 2023
pubmed: 27 9 2023
entrez: 27 9 2023
Statut: ppublish

Résumé

We aimed to compare health-related quality of life (HRQoL) by gout severity, overall and by sex. A questionnaire was sent to patients with gout (n = 1444) identified at 12 primary care centres in Western Sweden. The questionnaire asked about comorbidities, gout-specific aspects, and HRQoL, using the RAND 36-Item Health Survey. Responders were divided into 'mild', 'moderate', or 'severe' gout based on the number of self-reported flares (0, 1-2, ≥ 3) during the past 12 months. Out of 1444 gout patients, 784 (54.3%) responded to the questionnaire. Among the respondents, 673 [560 (83.2%) men and 113 (16.8%) women] provided answers regarding the number of gout flares in the past year. Of these, 322 (47.8%), 218 (32.4%), and 133 (19.8%) were classified as having mild, moderate, and severe gout, respectively. Allopurinol use was more frequent in those with mild disease. In more severe gout, HRQoL was reduced compared to less severe gout [severe vs mild gout, mean values for physical component summary (PCS) score 39.5 vs 43.6, p = 0.002, and mental component summary (MCS) score 46.6 vs 51.1, p < 0.001]. When excluding those with a flare in the past month, the HRQoL was still worse in severe gout (vs mild), although differences were attenuated and not statistically significant for the PCS and for women. Gout severity, defined as the number of flares during the past year, was associated with significant reductions in HRQoL.

Identifiants

pubmed: 37755229
doi: 10.1080/03009742.2023.2240596
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

683-688

Auteurs

A J Landgren (AJ)

Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Region Västra Götaland, Research and Development Primary Health Care, Gothenburg, Södra Bohuslän, Sweden.

Lth Jacobsson (L)

Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

E Klingberg (E)

Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

R Mirzaev (R)

Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

M Dehlin (M)

Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH